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Furan is formed in a variety of heat-treated foods through thermal degradation of natural food
constituents. Relatively high levels of furan contamination are found in ground roasted coffee,
instant coffee, and processed baby foods. European exposure estimates suggest that mean
dietary exposure to furan may be as high as 1.23 and 1.01 g/kg bw/day for adults and 3- to 12-
month-old infants, respectively. Furan is a potent hepatotoxin and hepatocarcinogen in rodents,
causing hepatocellular adenomas and carcinomas in rats and mice, and high incidences of
cholangiocarcinomas in rats at doses ≥2 mg/kg bw. There is therefore a relatively low margin
of exposure between estimated human exposure and doses that cause a high tumor incidence
in rodents. Since a genotoxic mode of action cannot be excluded for furan-induced tumor
formation, the present exposures may indicate a risk to human health and need for mitigation.
This review summarizes the current knowledge on mechanisms of furan formation in food,
human dietary exposure to furan, and furan toxicity, and highlights the need to establish the
risk resulting from the genotoxic and carcinogenic properties of furan at doses lower than
2 mg/kg bw.
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1 Introduction
Furan, a heterocyclic aromatic organic compound, is a color-
less, inflammable, and volatile liquid widely used in various
industrial processes, e.g. as an intermediate in the produc-
tion process of tetrahydrofuran, pyrrole, and thiophene, in
the manufacturing of lacquers and resins [1], and for the pro-
duction of pharmaceuticals, agricultural chemicals (insecti-
cides), and stabilizers. Furan also occurs in the environment
as a constituent of cigarette smoke, wood smoke, and ex-
haust gas from diesel and gasoline engines [1]. Moreover,
furan was shown to be present in a variety of food items that
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undergo heating processes [2], suggesting that humans may
be exposed to furan via food. Furan is a potent hepatotoxin
and hepatocarcinogen in rodents, and has been classified by
the International Agency for Research on Cancer (IARC) as
possibly carcinogenic to humans (group 2B) [1]. However, the
mechanisms of carcinogenesis are not clear and the relevance
of the effects to other related compounds such as dimethyl-
furan needs to be established.
2 Formation of furan in food
Heat-induced formation of furan in food can occur through
a variety of pathways. The most important food constituents
serving as precursors for furan production appear to be ascor-
bic acid, sugars, amino acids, and unsaturated fatty acids [3].
Model reactions with individual compounds or mixtures of
precursors provided important insight as to how furanmay be
formed during heating processes (Fig. 1). These experiments
revealed that the most efficient precursor for the formation
of furan is L-ascorbic acid, followed by dehydroascorbic acid,
glycolaldehyde/L-alanine, and D-erythrose [4].
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Figure 1. Summary of potential
routes of furan formation from dif-
ferent components present in food
(modified from [4]); PUFAs = polyun-
saturated fatty acids.
Formation of furan from polyunsaturated fatty acids (PU-
FAs) is initiated by oxidative degradation of PUFAs by reactive
oxygen species, resulting in the generation of a range of lipid
peroxidation products such as 2-alkenals, 4-oxo-alkenals, and
4-hydroxy-2-alkenals, including 4-hydroxy-2-butenal (Fig. 1).
4-Hydroxy-2-butenal can form furan through cyclization and
dehydration [4].
The mechanism of furan formation from amino acids
involves the production of two key molecules acetaldehyde
and glycolaldehyde [4]. Both aldehydes occur as impor-
tant intermediates in the thermal degradation of amino
acids and are able to undergo aldol addition. The result-
ing 2-deoxyaldotetrose can then further react to yield furan
(Fig. 1) [4].
Thermal degradation of the amino acids serine and cys-
teine can produce both acetaldehyde and glycolaldehyde,
whereas aspartic acid, -alanine, and threonine can give rise
to acetaldehyde only. Furan formation thus depends on the
presence of reducing sugars as a source for glycolaldehyde
[4]. This mechanism is consistent with data demonstrating
that heating of L-serine or L-cysteine leads to small amounts
of furan, whereas heating of L-aspartic acid, L-alanine, and
L-threonine alone does not result in detectable furan for-
mation [4]. However, furan was formed when D-glucose (a
source of glycolaldehyde)was added to the single amino acids.
Reactions of glycolaldehyde and L-alanine resulted in high
amounts of furan [4].
The formation of furan through thermal degradation
of sugars appears to involve formation of the reactive in-
termediates 1-deoxyosone and 3-deoxyosone, which further
react to aldotetrose derivatives, such as aldotetrose itself,
2-deoxyaldotetrose, and 2-deoxy-3-ketoaldotetrose (Fig. 1).
These molecules occur during degradation of hexoses and
pentoses. Aldotetrose derivatives as intermediates are also
involved in the formation of furan from the degradation of
ascorbic acid and dehydroascorbic acid.
Reaction conditions such as temperature, time, and pH
can significantly affect furan formation [5, 6]. For instance,
Fan et al. demonstrated a time- and temperature-dependent
increase in the formation of furan in fresh apple cider. Heat
treatment at 90C for 10 min produced no measurable fu-
ran, whereas heating to 120C resulted in a time-dependent
increase in furan production [6]. Importantly, the effect of
pH on furan formation may depend on the precursor from
which furan is formed. In a study investigating the influence
of pHon furan formation from sugars, ascorbic acid, and fatty
acids, highest amount of furan was formed from linoleic acid
at pH 6. In contrast, thermally induced furan formation in
a solution of ascorbic acid was significantly higher at pH 3
than at pH 6 [6].
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Table 1. Furan content in food per category [12]; LOQ = limit of quantification, LOD = limit of detection
Food category Total number Number of Number of Number of Range of Mean furan
of samples samples > LOQ samples ≤ LOD samples ≤ LOQ furan content [g content [g
furan/kg food] furan/kg food]
Roasted coffee (ground) 66 50 0 16 5–5749 1114
Instant coffee 48 41 0 7 8–2200 589
Baby food 985 778 59 148 0.03–215 25
Soups 198 158 15 25 0.7–225 24
Meat products 65 36 15 14 2–115 22
Infant formulas 35 27 3 5 2–56 19
Milk products 20 14 0 6 1–80 15
Cereal products 99 37 44 18 0.2–168 14
Sauces 207 10 19 88 0.1–120 12
Vegetables 95 28 7 60 1–74 12
Fruits 84 22 7 55 0.6–27 7
Vegetable juices 45 7 10 28 1–20 7
Beer 86 36 17 33 1–28 6
Fruit juices 203 69 32 102 0.5–420 6
3 Furan content in food and human
exposure
Since FDA scientists first identified furan in a number
of heat-treated food items [7], a large number of samples
from a wide variety of food categories that undergo heat
processing have been analyzed worldwide. Results from
these analyses have been published as individual reports
or assembled in online databases on furan content in food
[2, 7–13]. Representative data on furan in various food
categories reported by The European Food Safety Authority
(EFSA) are shown in Table 1. For most food categories, the
levels of furan vary over a wide range. By far the highest
contents are found in ground roasted coffee and instant
coffee [12, 13]. Scholl et al. [14] found up to 1912 g/kg
in powdered ground coffee. Moreover, maximal furan
contents of more than 100 g furan/kg food were found
in certain processed baby food, soups, cereals products,
meat products, and sauces, all prepared by temperature
treatments [12, 13]. Unexpectedly high concentrations of
furan or contradicting levels of contamination were also
reported for certain food categories such as fruit and
vegetables juices, nutrition drinks, and bakery products
[7, 13]. Thus, recent headspace gas chromatography analyses
conducted within the frame of an EU-funded project focused
on the analysis of furan in these food categories. High
furan levels were found in sterilized baby carrot juices, in
prune juices, and in different flavors of a particular type
of pharmaceutical nutrition drink [15]. Moreover, bakery
products, especially rye and wholegrain-based products,
showed high but highly varying furan levels [15]. These data
have been collected in a database that has been made public
(http://www.furan-ra.toxi.uni-wuerzburg.de/furan_ra_2007
_public_area/deliverablesresults_with_dissemination_level
_public/deliverable_82/), together with data on furan levels
in food from a large number of national, state, or federal
food safety agencies and universities.
Human exposure to furan was estimated based on food
consumption data and the content of furan in various food
items. In Europe, the estimated mean exposure of adults to
furan in food ranged from 0.34 to 1.23 g/kg bw/day in dif-
ferent member states, with a median of 0.78 g/kg bw/day
[12]. For infants at 3–12 months of age, an estimated mean
exposure between 0.27 and 1.01g/kg bw/day was calculated
[12]. Minorczyk et al. [16] measured furan concentrations in
infant foods and estimated an exposure range of 0.23–1.77
g/kg bw/day. In the case of adults, coffee was identified
as the main source of furan from food, while exposure of
infants to furan is considered to be predominantly caused
through intake of infant formulas and jarred baby food [12].
The relatively high level in hot coffee is intriguing in light
of the volatility of furan and there is the possibility of se-
questration within such products. Results from the recent
EU-funded project suggest that furan in canned or bottled
drinks may be another significant source of furan exposure,
particularly in children [15] (http://www.furan-ra.toxi.uni-wu
erzburg.de). Based on the determination of furan in juices
and drinks, a number of exposure scenarios can be defined
(Table 2) using average bodyweights and food intake assump-
tions. When compared to furan intake estimates by EFSA for
adult and 3–12 months babies, furan intakes from some of
the analyzed food items approach or even exceed the EFSA
values. US exposure estimates for furan are similar to those
made in Europe [17] for children, but are somewhat lower for
adults. The lower intake estimates for adults may be due to a
relatively low coffee consumption in the United States.
4 Toxicology of furan
4.1 Toxicokinetics and biotransformation of furan
Studies on furan toxicokinetics in rats indicate that furan is
rapidly absorbed from the gastrointestinal tract, extensively
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Table 2. Daily furan intake based upon samples analyzed
within the recent Furan-RA project (http://www.furan-ra.
toxi.uni-wuerzburg.de)
Consumer Assumed Body Median intake
type intake weight from all brands
(kg) analyzed
(g/kg bw)
Baby carrot juice
consumer
250 5 1.13
Baby fruit juice
consumer
250 5 0.29
Adult carrot juice
consumer
250 70 0.01
Adult strawberry
nutrition drink
consumer
1200 70 0.02
Adult nutrition drink
consumer
1200 70 0.4
metabolized, and eliminated via expired air, urine, and feces.
Within 24 h of administration of a single oral dose of [2,5-14C]-
furan (8 mg/kg bw) to male F344 rats, more than 80% of the
administered radioactivity was eliminated, with 14% exhaled
as unchanged furan, 26% exhaled as CO2, 20% excreted via
urine, and 22% via feces [18]. Most of the radioactivity still
present in rats after 24 h was recovered in the liver [18].
Repeated administration of [2,5-14C]-furan at daily doses of
8 mg/kg bw resulted in accumulation of radioactivity in the
liver [18].
Physiologically-based pharmacokinetic model simula-
tions of furan biotransformation after a single oral dose of
8 mg/kg bw predicted 14% of the administered dose exhaled
unchanged and 84% metabolized [19].
Furan ismetabolized by cytochromeP450 (CYP) enzymes,
predominantly CYP2E1, to its major metabolite cis-2-butene-
1,4-dial (BDA, maleic dialdehyde) [19, 20], a highly reactive
electrophile identified as the key mediator of furan toxic-
ity and carcinogenicity (Fig. 2). The activity of CYP2E1 to-
ward furan is similar between human and rat liver micro-
somes [21]. Cytochrome P450 mediated bioactivation of fu-
ran is supported by studies in rat hepatocytes, which demon-
strate that furan-mediated effects on glutathione (GSH) levels
and cell viability can be suppressed by the CYP inhibitor 1-
phenylimidazole and increased by pretreatment of rats with
acetone (a CYP2E1-inducing agent), indicating that furan cy-
totoxicity depends on itsmetabolic activation [22]. In line with
these findings, furan hepatotoxicity in female B6C3F1 mice
was prevented by cotreatment with the irreversible CYP450
inhibitor aminobenzotriazole [23].
BDA has been shown to react with cellular nucleophiles
such as GSH and amino acids and to cause cross-links be-
tween thiols and amino groups [24], giving rise to lactam
and pyrrole derivatives (Fig. 2). Studies on furan biotrans-
formation in rat hepatocytes and in rats in vivo demonstrate
formation of a complex spectrum ofmetabolites derived from
conjugation of BDA with GSH and amino acids (Fig. 3)
Figure 2. Cytochrome P450 mediated bioactivation of furan and
reactivity of cis-2-butene-1,4-dial toward amines (R-NH2) and thi-
ols (R-SH) (modified from [24]).
[25–29]. Due to the bifunctionality of BDA, intermediates
resulting from conjugation of BDA with GSH still remain
chemically reactive and have the potential to rapidly alky-
late free or protein-bound amino groups or perform intra-
and intermolecular reactions with the -amino group of the
GSH glutamyl residue to form bis-GSH adducts or cyclic
mono-GSH adducts [30] (Fig. 3). In vivo, the cyclic mono-
GSH conjugates were detected in both urine and bile of
furan-treated rats [26, 28], whereas several metabolites con-
sistent with enzymatic processing of the bis-GSH conjugates
by -glutamyltransferase located at the canalicular mem-
brane of hepatocytes were recently identified in rat bile [28].
These include a cysteinylglycine–BDA–GSH conjugate and a
cysteine–BDA–GSH conjugate, which may be formed by -
glutamyltransferase- and dipeptidase-dependent cleavage of
the GSH group linked to the pyrrole ring by its thiol group,
and a BDA cross-link between GSH and glutamic acid, which
may result from cleavage of the -glutamyl bond within the
GSH moiety contributing the amine in the pyrrole or by di-
rect reaction of thiol-BDA with the amino groups of gluta-
mate. In addition, several metabolites derived from BDA-
derived cross-links between cysteine and lysine, e.g. an N-
acetylcysteine-N-acetyllysine conjugate and the correspond-
ing sulfoxide, present biliary and/or urinary metabolites of
furan (Fig. 3) [28, 29]. These may be formed by conjugation
of BDA with GSH or cysteine and subsequent reaction with
(free or protein-bound) lysine, but may also represent degra-
dation products of protein adducts formed through the reac-
tion of BDA with protein-bound cysteine and lysine residues.
Indeed, a recent study suggests that a significant proportion
of lysine-derived furan metabolites stems from degradation
of protein adducts in which lysine is cross-linked by BDA to
GSHor protein thiols [25]. Interstingly, a putative oxidoreduc-
tase (ucpA) offers resistance to furan in Escherichia coli [31]
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Figure 3. Proposed metabolic pathways of furan based on metabolites identified in hepatocyte cultures (h) and/or urine (u) or bile (b) of
rats exposed to furan. Note that conjugation of cis-butene-1,4-dial (BDA) with glutathione (GSH) or cysteine can occur in position 2 and 3
of the resulting pyrrol ring. For reasons of clarity, only 3-substituted metabolites are shown.
and, once this gene product has been characterized, it may
offer leads to relationships between metabolism and toxicity.
4.2 Oral toxicity of furan as the most relevant route
of human exposure via food
4.2.1 Rats
Due to the relatively high activity of CYP2E1 to bioactivate
furan to its reactive intermediate, the liver is the main target
organ of furan toxicity [32]. Male F344 rats given a single dose
of 30 mg/kg bw furan by oral gavage showed hepatocellular
necrosis, inflammation, and elevated liver enzyme activities
in the serum within 24 h of furan administration, followed
by regenerative cell proliferation (48 h) and residual inflam-
mation after 8 days [33]. Similar to the single dose, exposure
of Sprague-Dawley rats to furan at 40 mg/kg bw for up to
14 days resulted in decreased body weights, increased relative
liver weights, and significant increases in serum transam-
inases, alkaline phosphatase, cholesterol, triglycerides, and
total bilirubin, along with increased blood urea nitrogen and
serum creatinine indicative of impaired hepatic and renal
function [34]. Microscopic treatment-related changes in rat
liver included hepatocellular degeneration, hepatic inflam-
mation, and compensatory processes including hepatocellu-
lar cytomegaly, mitosis, and regenerative hyperplasia in re-
sponse to hepatocyte loss [34]. Proliferative lesions involving
the biliary tract consisted of biliary hyperplasia characterized
by increased numbers of bile ducts, cholangiofibrosis, and
oval cell hyperplasia [34]. In the kidney, furan treatment re-
sulted in renal cortical tubular necrosis and regeneration [34].
In a 13-week oral toxicity study inmale and female F344/N
rats conducted at doses of 0, 4, 8, 15, 30, and 60 mg/kg bw,
nine of ten male and four of ten female rats treated with
60 mg/kg bw died before the end of the study [32]. Rela-
tive liver weights were significantly increased in males given
15 and 30 mg/kg bw, and in females in the 15, 30, and
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60 mg/kg bw dose groups [32]. Toxic lesions of the liver
consisted of bile duct hyperplasia and cholangiofibrosis at
doses ≥4 mg/kg bw, and hepatocyte cytomegaly, degenera-
tion, and nodular hyperplasia at doses ≥8 mg/kg bw [32]. In
contrast, histopathological changes involving the renal tubule
epithelium were recorded in the high-dose group only. From
these studies, a no observed adverse effect level (NOAEL)
for furan hepatotoxicity could not be established. To address
furan toxicity in the low-dose range closer to potential hu-
man exposures, Gill et al. recently investigated macroscopic
and histological changes in livers of male and female F344
rats after 90 days of oral treatment with furan doses of 0.0,
0.03, 0.12, 0.5, 2.0, and 8.0mg/kg bw [35]. Grossmorphologic
changes characterized by nodular structures were observed in
livers of all high-dose animals, with the caudate and left lateral
lobe being most affected [35]. This is consistent with previ-
ous reports indicating that the subcapsular visceral surfaces
of the left lateral, caudate, and right posterior liver lobes are
particularly susceptible to furan toxicity [33, 34, 36, 37]. Mild
histopathological changes consisting of hepatocyte apopto-
sis, Kupffer cell pigmentation, and foci of inflammatory cells
were evident at doses of ≥0.12 mg/kg bw [35]. At these dose
levels, the changes were restricted to the subcapsular visceral
surface of the left lateral and caudate lobes. However, with
increasing doses, the lesions became more pronounced and
extended deeper into the liver lobe. At the highest dose of 8
mg/kg bw, subcapsular inflammation, hyperplasia of biliary
epithelial cells, and cholangiofibrosis with fibrotic tissue re-
placing the liver parenchyma were reported [35]. Based on
these findings, 0.03 mg/kg bw was established as a NOAEL
for furan hepatotoxicity in rats.
4.2.2 Mice
Studies in mice indicate that furan induces similar hepatic
lesions inmice as in rats, althoughmice appear to be less sus-
ceptible to furan hepatotoxicity. Treatment of male B6C3F1
mice with a single oral furan dose of 50 mg/kg bw induced
hepatocellular degeneration, necrosis, inflammation, and in-
creased liver enzymes in plasma after 12 h, showing themost
extensive response at 24 h postdose [33]. By 48 h, inflam-
mation and a strong increase in cell proliferation were ob-
served [33]. In a subacute toxicity study, oral treatment of
male B6C3F1 mice with 15 mg/kg bw furan for up to 6
weeks caused necrosis and inflammation within the subcap-
sular parenchyma but did not induce bile duct proliferation,
which contrasts the bile duct hyperplasia and peribiliary fi-
brosis observed in rats [33]. In a 13-week oral toxicity study,
B6C3F1 mice were administered 0, 4, 8, 15, 30, or 60 mg/kg
bw (females) and 0, 2, 4, 8, 15, or 30 mg/kg bw (males) [32].
Mice of all dose groups and both sexes showed increased
relative liver weights and toxic lesions of the liver consisting
of hepatocellular cytomegaly, degeneration, and necrosis [32].
In contrast, bile duct hyperplasia and cholangiofibrosis were
only observed at 30 or 60 mg/kg bw furan.
To obtain dose-response data in the lower dose range
closer to estimated human exposures, male and female
B6C3F1 mice were treated with furan at 0.0, 0.03, 0.12, 0.5,
2.0, and 8.0 mg/kg bw by gavage for 90 days [38]. Increased
absolute and relative liver weights were observed in the fe-
males at the highest dose, while no changes in these param-
eters were detected in males. In both sexes, serum alanine
aminotransferase levels were found to be significantly in-
creased at the highest dose of 8 mg/kg bw [38]. In the caudate
lobes, lightmicroscopic examination of liver sections revealed
mild to moderate subcapsular lesions including hepatocellu-
lar apoptosis, altered Kupffer cells, oval cell hyperplasia, and
inflammation at doses of ≥2 mg/kg bw in both sexes and
in a single male at 0.5 mg/kg bw. In addition, some animals
treated with the highest dose of 8mg/kg bw showed slight hy-
perplasia of bile ducts. Similar changes were observed in the
left lobes at doses of ≥2 mg/kg bw in both sexes, although no
biliary hyperplasia was found in these lobes. In the right and
median lobes, histopathological alterations were only rarely
seen in singular animals. Based on this study, a NOAEL of
0.12 mg/kg bw was derived.
4.3 Carcinogenicity of furan
4.3.1 Rats
Chronic toxicity and carcinogenicity of furan was investigated
in F344/N rats administered furan at doses of 0, 2, 4, and 8
mg/kg bw by oral gavage [32]. In this study, various non-
neoplastic hepatic lesions similar to those seen after sub-
chronic treatment at higher doses were reported in rats of
both sexes [32]. Furan significantly increased the combined
incidence of hepatocellular adenomas and carcinomas in
male F344/N rats (Table 3). Furthermore, furan was reported
to cause high incidences of cholangiocarcinomas inmale and
female F344/N rats after 2 years of furan administration at all
three dose levels (Table 3) [32]. Cholangiocarcinomas accom-
panied by cholangiohepatitis were also recorded at the 9- and
15-month interim sacrifices in all treatment groups. In a stop-
exposure study, 3-month treatment with 30 mg furan/kg bw
was sufficient to produce 100% incidence of cholangiocarci-
noma within 9–15 months without further treatment [32,37].
Cholangiocarcinomas in furan-treated rats were character-
ized by “a connective tissue stroma . . . interspersed between
multiple biliary glands and cysts (markedly dilated glands)
lined by biliary epithelial cells that varied considerably inmor-
phologic features” [37]. Epithelium lining dilated glands con-
sisted of mitotically active flattened or cuboidal to columnar
epithelial cells, accompanied by mucous-secreting epithelial
cells and inflammatory cell infiltrates in the stroma and cystic
lumen [37]. Although there appears to be some debate with
regard to the malignant nature of such lesions, the morpho-
logical features and growth characteristics of furan-induced
cholangial lesions, including cellular dysplasia, infiltrating
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Table 3. Tumor incidences in F344/N rats and B6C3F1 mice after chronic administration of furan [32]
Sex 0 mg/kg bw 2 mg/kg bw 4 mg/kg bw 8 mg/kg bw 15 mg/kg bw
F344/N rats
Cholangiocarcinoma ♂ 0/50 43/50 48/50 49/50 n.a.♀ 0/50 49/50 50/50 48/50 n.a.
Hepatocellular ade-
noma/carcinoma
♂ 1/50 5/50 22/50 35/50 n.a.
♀ 0/50 2/50 4/50 8/50 n.a.
B6C3F1 mice
Hepatocellular
adenoma /
carcinoma
♂ 26/50 n.a. n.a. 44/50 50/50
♀ 7/50 n.a. n.a. 34/50 50/50
growth into the adjacent hepatic parenchyma, progressive
growth after cessation of treatment, metastatic potential, and
progressive growth and metastasis of 4 of 21 primary tumors
transplanted into recipient F344 rats, were seen as convincing
evidence for the malignancy of the tumors [37].
4.3.2 Mice
In contrast to rats, cholangiocarcinomas were not observed
inmale or female B6C3F1mice treated with furan at 8 and 15
mg/kg bw for 2 years [32]. However, the combined incidence
of hepatocellular adenomas and carcinomas was significantly
increased to up to 100% in mice of both sexes dosed with
furan at 8 and 15mg/kg bw (Table 3) [32]. In a recent carcino-
genicity study conducted at lower doses than in the original
National Toxicology Program (NTP) bioassay, female B6C3F1
mice received 0.5, 1, 2, 4, or 8 mg/kg bw furan by gavage for 2
years [39]. At doses of 4 and 8mg/kg bw furan, the incidences
of liver nodules, foci of altered hepatocytes, and hepatocellu-
lar adenomas or carcinomas were found to be significantly
increased.
5 Mechanisms of furan carcinogenicity
5.1 Genotoxicity of furan
Results of in vitro and in vivo studies on furan genotoxicity are
largely inconsistent (Table 4). It is possible that some of the
in vitro tests were hindered by loss of furan concentrations
through volatility. Furan was not mutagenic in Salmonella ty-
phimurium strains TA100, TA1535, TA1537, and TA98 with
and without S9 metabolic activation [32], and no genotoxic ef-
fects were observed in L5178Y tk(+/–)mouse lymphoma cells
(strandbreaks,micronuclei, and tk+/− mutations) [40] andhu-
man lymphocytes (micronuclei) with or withoutmetabolic ac-
tivation [41]. However, furan reduced the percentage of DNA
in the comet tail in turkey liver fetal hepatocytes indicating
the presence of DNA–protein cross-links and to increase the
percentage of DNA in the comet tail after proteinase K treat-
ment [42]. Furan was also shown to induce chromosomal
aberrations and sister chromatid exchanges (SCEs) in Chi-
nese hamster ovary (CHO) cells [32]. Consistent with these
findings, a small increase in SCEs was also observed in a
Chinese hamster V79 derived cell line stably expressing hu-
man cytochrome P450 (CYP) 2E1 (V79-hCYP2E1-hSULT1A1
cells) required for bioactivation of furan to BDA [43]. In vivo,
chromosomal aberrations, but no SCEs, were found inmouse
bone marrow cells after intraperitoneal administration of fu-
ran [32]. Furan did not induce unscheduled DNA synthesis
(UDS) inmouse or rat hepatocytes in vivo and in vitro [32,33].
Furan was also negative in the micronucleus test in mouse
peripheral blood erythrocytes [41]. Similarly, no -H2AX foci,
DNA strand breaks, or cross-links were detected in livers of
mice under bioassay conditions [44]. However, a statistically
significant increase of micronucleated cells was recently re-
ported in the spleen of furan-treated mice [45]. Importantly,
a recent study in the transgenic Big Blue rat model found no
evidence for furan mutagenicity in vivo by a range of assays
(Pig-a and Hprt gene mutation and liver cII transgene muta-
tion assay), although liver DNA damage was observed by the
Comet assay at doses higher than the cancer bioassay doses
[46]. In contrast, a reduction of percentage of DNA in comet
tail in liver cells was observed following treatment of turkey
fetuses in ovo [42]. Since DNA strand breaks were then in-
creased by treatment of hepatocytes with proteinase K, it was
suggested that DNA–protein cross-links had been formed by
furan.
In contrast to furan, its reactive metabolite BDA was re-
ported to be mutagenic in the Ames test in a strain sensitive
to aldehydes (TA 104) [47], although these results could not be
reproduced by an independent group [40]. In one study, BDA
was shown to causeDNA single-strand breaks and cross-links
in CHO cells [48]. In L5178Y tk+/− mouse lymphoma cells,
BDA induced DNA strand breaks and tk+/− gene mutations
in a narrow concentration range but did not cause micronu-
clei and cross-links [40].
While Byrns et al. demonstrated that BDA readily re-
acts with 2’-deoxyribonucleosides in vitro to form sub-
stituted 1,N6-etheno-2’-deoxyadenosine and 1,N2-etheno-2’-
deoxyguanosine adducts [49] (Fig. 4), formation of these
adducts in rat liver in vivo and their contribution to
furan carcinogenicity remain to be established. A study
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Table 4. Results of assays on mutagenicity and genotoxicity of furan and its metabolite BDA in vitro and in vivo
In vitro
Test system Test item Concentration Results Reference
Mutagenicity in bacteria
S. typhimurium TA100, TA1535, TA1537,
and TA98
Furan 0, 33, 100, 333, 1000, 3330,
10,000 pg/plate
Negative (+/– meta bolic
activation)
[32]
S. typhimurium TA97, TA98, TA100, and
TA102
BDA 1.4, 1.7, 2.1, 2.9, 4.3 mol/plate Negative [47]
S. typhimurium TA104 BDA 1.4, 1.7, 2.1, 2.9, 4.3 mol/plate Positive [47]
Mutagenicity in mammalian cells
L5178Y tk(+/–) mouse lymphoma cells Furan 0, 0.25, 0.5, 1, 2, 4 g/L, 4 h Negative [40]
L5178Y tk(+/–) mouse lymphoma cells BDA 0, 6.3, 12.5, 25, 50 M, 4 h Positive [40]
L5178Y tk(+/–) mouse lymphoma cells Furan 125–3800 g/mL, 4 h Positive [32]
DNA strand breaks
L5178Y tk(+/–) mouse lymphoma cells Furan 0, 0.25, 0.5, 1, 2, 4 g/L, 4 h Negative [40]
L5178Y tk(+/–) mouse lymphoma cells BDA 0, 6.3, 12.5, 25, 50 M, 4 h Positive [40]
Chinese hamster ovary cells BDA 0.17, 0.5, 1.5 mM Positive [48]
Micronuclei test
L5178Y tk(+/–) mouse lymphoma cells Furan 0, 0.25, 0.5, 1, 2, 4 g/L, 4h Negative [40]
L5178Y tk(+/–) mouse lymphoma cells BDA 0, 6.3, 12.5, 25, 50 M Negative [40]
Sister chromatid exchange
Chinese hamster ovary cells Furan 0, 1.6, 5, 16, 50, 160, (500)
g/mL
Positive [32]
V79-hCYP2E1-hSULT1A1 cells Furan 3–16 000 M Positive [43]
Chromosomal aberration
Chinese hamster ovary cells Furan 0, 100, 160, 300, 500, 1000
g/mL
Positive [32]
Chinese hamster ovary cells Furan up to ∼200 mM Positive [64]
In vivo
Test system Test item Dose Results Reference
Unscheduled DNA synthesis
Mouse liver Furan 200 mg/kg bw, (oral) Negative [32]
Rat liver Furan 100 mg/kg bw (oral) Negative [32]
Mouse liver Furan 10, 50, 100, 200 mg/kg bw (oral) Negative [33]
Rat liver Furan 5, 30, 100 mg/kg bw (oral) Negative [33]
DNA strand breaks
Mouse liver Furan 2, 4, 8, 15 mg/kg bw (oral
gavage for 28 days)
Negative [44]
Mouse liver Furan 15, 100, 250 mg/kg bw Positive at 250 mg/kg bw [44]
Rat liver Furan 2, 4, 8, 16, 30 mg/kg bw (oral
gavage for 8 weeks, 5
days/week)
Positive at ≥16 mg/kg
bw
[46]
Micronuclei test
Mouse peripheral blood erythrocytes Furan 0–300 mg/kg bw (i.p.)
0–275 mg/kg bw (s.c.)
Negative [41]
Mouse splenocytes Furan 0, 2, 4, 8, 15 mg/kg bw (oral
gavage for 4 weeks, 5
days/week)
Positive [45]
Rat peripheral blood reticulocytes Furan 2, 4, 8, 16 30 mg/kg bw (oral
gavage for 8 weeks, 5
days/week)
Negative [46]
Sister chromatid exchange
Mouse bone marrow cells Furan 25, 50, 100 mg/kg bw (i.p.)
87.5, 175, 350 mg/kg bw (i.p.)
Negative [32]
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Table 4. Continued
In vivo
Test system Test item Dose Results Reference
Chromosomal aberration
Mouse bone marrow cells Furan 87.5, 175, 350 mg/kg bw (i.p.)
62.5, 125, 250 mg/kg bw (i.p.)
Positive [32]
Mutations
Rat red blood cells (Pig-a mutations) Furan 2, 4, 8, 16 30 mg/kg bw (oral
gavage for 8 weeks, 5
days/week)
Negative [46]
Rat spleen lymphocytes (Pig-a and Hprt mutations) Furan 2, 4, 8, 16 30 mg/kg bw (oral
gavage for 8 weeks, 5
days/week)
Negative [46]
Rat liver (cII mutant frequency) Furan 2, 4, 8, 16 30 mg/kg bw (oral
gavage for 8 weeks, 5
days/week)
Negative [46]
Figure 4. Reactivity of cis-2-butene-1,4-dial toward DNA bases.
addressing the potential of furan to bind to DNA in vivo
found no radioactivity associated with liver DNA after admin-
istration of [2,5-14C]-furan to rats [18]. However, the failure
to detect furan-derived DNA adducts in this study may have
been due to the relatively low specific activity of [2,5-14C]-furan
(90 Ci/mmol) and labeling at the labile carbons (2 and 5),
which may give rise to CO2 [2], resulting in low sensitivity.
Thus, results from this study were considered inconclusive
[2]. In contrast to the study by Burka et al. [18], a recent ac-
celerator mass spectrometry study in which rats were dosed
with [3,4-14C]-furan (20 mCi/mmol) at 0.1 and 2 mg/kg bw
found significant dose-dependent DNA binding in rat liver
and kidney as a nontarget organ of carcinogenicity [50]. The
nature of the covalent modifications (e.g. DNA base adducts
versusDNA–DNAorDNA–protein cross-links) remains to be
identified. However, it is interesting to note that subchronic
treatment with furan in the same dose-range did not induce
mutagenicity, liver DNA damage, or changes in the expres-
sion of genes involved in DNA damage response [46,51]. This
is in contrast to studies showing liver DNA damage and/or
altered expression of genes related to DNA damage response
in rats exposed to a much higher dose of furan (≥16 mg/kg
bw) and in male B6C3F1 mice treated with 15 mg/kg bw
for 4 weeks [44, 46, 52, 53]. However, no evidence for furan
mutagenicity was obtained even in this high-dose range [46].
5.2 Nongenotoxic mechanisms of furan
carcinogenicity
Irrespective of furan genotoxicity, results from a range of
studies suggest that furan carcinogenicity may at least in part
be mediated through nongenotoxic mechanisms or through
indirect DNA damage through reactive oxygen formation.
In particular, it is becoming increasingly clear that expo-
sure to furan at doses associated with increased tumor inci-
dences initially causes hepatocellular necrosis, accompanied
by inflammation and sustained regenerative proliferation of
hepatocytes, which may present key events in furan-induced
hepatocellular carcinogenicity. Persistent proliferation of bil-
iary and mesenchymal cells extending into the injured liver
parenchyma—presumably as part of a repair response to
replace the necrotic tissue—then leads to the development
of cholangiofibrosis and intestinal type metaplasia as pre-
cursors for cholangiocarcinoma. It is feasible that different
mechanisms contribute to carcinogenicity at different dose
levels.
C© 2012 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.mnf-journal.com
1206 S. Moro et al. Mol. Nutr. Food Res. 2012, 56, 1197–1211
5.2.1 Hepatocyte degeneration due to bioactivation
of furan to a reactive metabolite
Several independent studies in rats and mice given a single
high dose of furan (≥30mg/kg bw) demonstrate that subcap-
sular and centrilobular necrosis accompanied by markedly
increased liver enzymes is the primary response to furan
treatment [32,33,36]. Upon repeated administration of furan
to rats and mice at carcinogenicity bioassay doses, hepato-
cyte degeneration and associated inflammatory cell infiltrates
were initially recorded at the subcapsular visceral surface of
furan target lobes, from where they extended into the liver
parenchyma [33, 35, 38, 39].
Although various hypotheses have been put forward, the
reason for the differential lobe and site susceptibility to furan
toxicity evident from toxicity and gene expression [34] studies
remains to be established. Considering the close anatomical
proximity of susceptible areas to the stomach, Wilson et al.
speculated that orally administered furan may directly dif-
fuse from the stomach into the subcapsular area of target
lobes [33]. Alternatively, intra- and interlobular differences in
furan metabolism [54] or blood flow and thus furan delivery
may contribute to the regional differences in susceptibility
to furan [34, 55]. Finally, it is possible that vascular lesions
may constrict the blood flow in specific areas and thus induce
hypoxia and subsequent necrosis [56], although histopatho-
logical evaluation suggests that the endothelium is unaffected
by furan [36].
While millimolar concentrations of furan may disrupt
membrane integrity through a solvent effect, furan cytotoxic-
ity at concentrations that reflect in vivo dosimetry after hepato-
toxic doses (2–100M) [22] depends on cytochrome P450 2E1
mediated bioactivation of furan to its reactive intermediate
cis-2-butene-1,4-dial [22]. cis-2-butene-1,4-dial readily reacts
with amino- and sulfhydryl groups of free or protein-bound
amino acids. Consistent with the chemical reactivity, 80% of
the radioactivity present in livers of rats 24 h after adminis-
tration of 14C-labeled furan was found to be associated with
proteins [18]. These data suggest that disruption of protein
function through covalent binding to proteins critical to cell
fate may present a key step in furan cytotoxicity. However,
despite the established link between protein binding of reac-
tive intermediates and cytotoxicity, the cellular andmolecular
consequences of toxic electrophile insult are still poorly un-
derstood. Although protein interactionsmay be implicated in
cytotoxicity, the relevance to carcinogenicity is not known.
There is some evidence to suggest that mitochondria may
present preferential cellular targets of furan. Mugford et al.
found that furan cytotoxicity in isolated hepatocyte suspen-
sions was preceded by an irreversible loss of ATP due to un-
coupling of oxidative phosphorylation [57]. Toxicogenomics
data showing altered expression of genes involved in mito-
chondrial function and hepatic metabolism in livers of rats
treatedwith hepatotoxic doses of furan also indicate that furan
may interfere with mitochondrial energy production [34, 58].
A recent proteomics analysis demonstrating covalent bind-
ing of [14C]-furan to a large number of mitochondrial and
cytosolic proteins participating in glucose, amino acid, and
fatty acid metabolism supports a mechanistic link between
protein adduct formation and perturbation of hepatic energy
metabolism [59].
5.2.2 Inflammation and oxidative stress may
aggravate tissue injury
Kupffer cells filled with pigment and accumulation
of mononuclear cells and neutrophils indicative of an
inflammatory response are consistently recordedwithin areas
of subcapsular and centrilobular necrosis induced by furan
[33–36]. The involvement of inflammatory processes in furan
toxicity is also reflected by increased expression of cytokines
and other inflammation-associated genes [34,52,58], such as
IFN-, IL-1, IL-6, IL-10, and components of the complement
system [58], which may, however, also derive from lesions in-
volving the biliary tract. Irrespective, it is well established
that activation of resident macrophages and recruitment of
mononuclear cells/neutrophils may not only contribute to
liver regeneration but can also exacerbate tissue injury and
promote carcinogenesis through release of reactive oxygen
and nitrogen intermediates. Indeed, increased production of
reactive oxygen species in response to furan is suggested by
immunohistochemical detection of 8-oxo-dG within nuclei of
hepatocytes of centrilobular areas following high-dose expo-
sure [52] and changes in the expression of genes responsive
to oxidative stress in rats and/or mice [44,52,58]. In addition
to inflammation-mediated effects, cytochrome P450 2E1 de-
pendent release of reactive oxygen species has been associated
with metabolism of CYP2E1 substrates [60]. Moreover, sev-
eral of the recently identified target proteins of furan reactive
metabolites such as thioredoxin and peroxiredoxin partici-
pate in maintenance of redox homeostasis, suggesting that
increased production of reactive oxygen species coupled with
impaired antioxidant defensemay contribute to furan toxicity
and carcinogenicity through DNA oxidation [59].
5.2.3 Regenerative hepatocellular proliferation in
response to tissue injury
Compensatory hepatocyte proliferation in response to furan
toxicity is documented by a wide range of studies in rats and
mice. Wilson et al. demonstrated that midzonal and subcap-
sular necrosis induced inmale B6C3F1mice and F344 rats by
treatment with a single high dose of furan (mice: 50 mg/kg
bw; rats: 30 mg/kg bw) was followed by a marked increase
in hepatocyte proliferation as assessed by incorporation of
3H-thymidine [33]. After repeated administration of the high-
est carcinogenicity bioassay dose (mice: 15 mg/kg bw; rats:
8 mg/kg bw) for 6 weeks, the hepatocyte-labeling index was
significantly increased throughout the course of the study,
suggesting that sustained cell proliferation subsequent to
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cytotoxicity presents an early event during tumor develop-
ment in rodents exposed to furan [33].
Similar results were obtained in male and female B6C3F1
mice treated with furan in the same dose range [23, 44]. In
a recent study in female B6C3F1 mice exposed to 0.5, 1, 2,
4, or 8 mg/kg bw furan by gavage for 3 weeks or 2 years,
evidence for hepatotoxicity and enhanced hepatic cell prolif-
eration was observed at doses of ≥1 mg/kg bw furan, while
the incidence of hepatocellular adenomas or carcinomas was
increased only at doses of ≥4 mg/kg bw furan [39]. Based on
these findings, the authors concluded that there is a threshold
for furan hepatocarcinogenicity in mice, with a low level of
cytotoxicity being not sufficient to produce tumors [39]. This
has important implications for risk assessment since a re-
cent investigation of furan toxicity in mice derived a NOAEL
of 0.12 mg/kg bw/day for furan hepatotoxicity.
In the rat, there is also evidence to show that furan at
doses lower than the ones applied in the 2-year bioassay may
induce hepatotoxicity and compensatory cell replication. As-
sessment of hepatocyte proliferation in subcapsular areas of
the left and caudate lobes ofmale F344 rats treated with 0, 0.1,
0.5, and 2mg/kg bw furan for 4 weeks revealed a dose-related
increase in the BrdU-labeling index. Although statistical sig-
nificance was only reached at 2 mg/kg bw [56], changes in the
rate of cell proliferation were accompanied by a statistically
significant increase in the expression of genes involved in the
processes of apoptosis and cell cycle even at the lowest dose
of 0.1 mg/kg bw [51]. These findings are in line with a recent
90-day toxicity study in F344 rats orally treated with furan
doses of 0.0, 0.03, 0.12, 0.5, 2.0, and 8.0 mg/kg, from which a
NOAEL of 0.03 mg/kg bw/day was derived [35, 38]. Whether
the degree of tissue damage and associated regenerative cell
proliferation at these low doses within 100-fold of human ex-
posure will ultimately result in formation of hepatocellular
adenomas and carcinomas in rats following long-term expo-
sure remains to be established. Based on our current under-
standing, however, the minimal cytotoxicity and hepatocyte
proliferation restricted to subcapsular regions at low doses
would not explain the development of cholangiocarcinomas
that appear to require extension of tissue injury into the liver
parenchyma (see below).
5.2.4 Early and persistent biliary cell proliferation as
a repair process to replace necrotic tissue
In a study conducted to elucidate the sequential events in-
volved in the development of cholangiocarcinomas in furan-
treated rats, furan administered at daily doses of 30 mg/kg
bw was shown to cause subcapsular and centrilobular necro-
sis and inflammation within 24 h after the first dose [36].
By day 3 of the study, centrilobular lesions were largely re-
paired throughproliferation of hepatocytes and inflammation
was absent in these areas. In focal regions with more severe
injury extending into portal areas, however, hepatocyte pro-
liferation appeared to be insufficient for tissue regeneration
andwas accompanied by bile duct proliferation and sustained
inflammation. Cells within bile ducts extending into the liver
parenchyma differentiated into hepatocytes in what appeared
to present an ordered biliary to hepatocyte repair process to
replace the necrotic tissue. Ordered conversion into hepato-
cytes was evidenced by a loss of biliary markers such as OV-6,
BD1, and Cx43 at the transitional zone between cell pheno-
types. Importantly, these areas, in which normal sinusoidal
structure was maintained, were not associated with signifi-
cant inflammation and matrix deposition. However, in some
regions where the initial injury had been severe, the hepato-
cyte stem cell repair response was perturbed and biliary ducts
continued to extend into the parenchyma, with some ducts
acquiring an intestinal phenotype with a columnar ap-
pearance and prominent brush border characteristic of the
intestinal-type cholangiocarcinoma that later develops in
furan-treated rats. Successively, the hepatic parenchyma was
replaced by an abnormally expanding ductal system with mi-
totically active cells, vascular remodeling of sinusoids, and
deposition of connective tissue, leading to cholangiofibrosis
and eventually cholangiocarcinomas [36].
These investigations suggest that one mechanism of in-
duction of cholangiocarcinomas in furan-treated rats may
be dependent on an overwhelming of the capacity for adap-
tive repair following irretrievable hepatocyte loss associated
with proliferative metaplasia and cholangiofibrosis. In addi-
tion to acute treatment with high doses of furan (30 mg/kg
bw), early hepatic changes implicated in the pathogenesis
of furan-induced cholangiocarcinoma, i.e. biliary hyperplasia
and cholangiofibrosis, were evident following repeated ad-
ministration of bioassay doses (≥2 mg/kg bw) [33, 35], thus
correlating with tumor outcome. In contrast, furan doses
≤0.5 mg/kg bw did not produce lesions involving the bil-
iary tract, potentially indicating a threshold for induction
of cholangiocarcinoma in rats through the above proposed
mechanism. However, whether or not doses below the pre-
viously tested bioassay doses cause cholangiocarcinoma fol-
lowing chronic administration, potentially through a different
mechanism, remains to be seen. If the irreversible hepatocyte
loss at high dose contributes to carcinogenesis, a nonlinear
dose response relationship would be expected. In this regard,
a large-scale 2-year carcinogenicity study in male F344 rats at
furan doses of 20–2000g/kg bw/day presently conducted by
the National Center for Toxicological Research will provide
critical information on the shape of the dose response in the
low-dose range.
In a recent 90-day study in mice, mild focal bile duct hy-
perplasia was recorded in individual animals treated with
the bioassay dose of 8 mg/kg bw [38], consistent with non-
neoplastic lesions of the biliary tract characterized by bile duct
hyperplasia, inflammation, and fibrosis, seen after chronic
exposure of mice to furan in the same dose range [32].
Similarly, hyperplastic bile ducts, sometimes surrounded by
fibrous tissue, were observed following administration of fu-
ran at 30 and 60 mg/kg bw for 90 days [32]. Thus, it ap-
pears that furan induces essentially the same type of non-
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Table 5. Application of the MoE approach to furan-induced tumor incidences (HCC= hepatocellular carcinoma; CC= cholangiocarcinoma),
based on the BMDL10 and different exposure scenarios (European average and high consumers) in adults and infants [62,65]
Carthew et al. [62] JECFA [65]
Exposure MoE for BMDL10 HCC, MoE for BMDL10 CC, Exposure MoE for BMDL10 HCC,
(g/kg ♂ Rat (1.28 mg/ ♂ Rat (0.0012 mg/ (g/kg bw/day) ♀mice (0.96
bw/day) kg/day) kg/day) mg/ kg/day)
Average adult 0.8 1600 1.5 1.0 960
High adult consumer 1.75 750 0.7 2.0 480
Average infant 0.3 4300 4 - -
High infant consumer 1.0 1000 1.2 - -
neoplastic lesions involving the biliary tract with associated
increases in plasma bile acids [23, 56] in mice as in rats, al-
though with lesser severity. In contrast to rats, however, these
lesions do not appear to progress to the tumor stage. A fur-
ther response relevant to carcinogenesis is that ofmodulation
of DNA methylation. Although effects on DNA methylation
(along with modulation of expression of genes involved in
DNA damage response) were observed at 30mg/kg bw repeat
dosing [53], a lower dose of 2 mg/kg bw led to gene expres-
sion changes in the liver of rats without detectable modula-
tion of DNA methylation [51], again suggesting dose-specific
mechanisms.
6 Risk assessment
Based on the presently available data, it appears that both
genotoxicity and chronic cytotoxicity may contribute to furan-
induced tumor formation. However, different mechanisms
may be involved in the formation of hepatocellular carcinoma
in rats/mice and cholangiocarcinoma in rats, and the contri-
bution of DNA binding to the development of these different
tumor types as well as human relevance of cholangiocarci-
noma remain to be established.
In a recent opinion, the Scientific Committees of the
European Commission evaluated the currently used method-
ologies for risk assessment of genotoxic carcinogens. These
methodologies include: linear extrapolation from high doses
in repeated dose animal studies to low-dose human expo-
sure, the margin of exposure (MoE) approach, and threshold
of toxicological concern (TTC) [61].
While the TTC concept is applied for compound that
lack toxicity data, linear extrapolation of the animal data on
furan to calculate possible human tumor risks is uncertain
because of the high incidence of tumors induced by furan
even at the lowest applied dose. A systematic application
of the MoE concept is also difficult since benchmark doses
or T25 cannot be calculated with sufficient certainty based
on the available tumor data. However, acknowledging
the uncertainties in deriving a BMDL from the previous
NTP study, the MoE approach was recently applied to
furan-induced hepatocellular carcinoma incidences [62],
resulting in MoEs for adults of 750–4300 for the BMDL10
(Table 5), and from 9000 to 5300 for the T25, depending
on the exposure scenario applied (US or Europe; average or
high-level exposure). For children, the estimated margins
were relatively similar, from 1000 to 4300 (Table 5) and
1600 to 5300, respectively, for BMDL10 and T25. While an
MoE of ≥10 000 is suggested to present a low concern for
a genotoxic carcinogen, these estimated margins for both
adults and children well below 10 000 and thus indicate
a need for risk reduction. Similarly, the Joint FAO/WHO
Expert Committee on Food Additives calculated MoEs of
480 and 960 for high and mean dietary exposures based
on hepatocellular adenoma and carcinoma in female mice
(Table 5) and concluded that these “indicate a human health
concern for a carcinogenic compound that might act via a
deoxyribonucleic acid (DNA) reactive genotoxic metabolite”
(http://www.fao.org/ag/agn/agns/jecfa/JECFA72%20Sum
mary%20Version%2016%20%20Mar%20FINAL%20rev%20
(2).pdf). In a study of the Belgian population that used both
a deterministic and a probabilistic method of estimating
daily intake and the BMDL10 for hepatocellular adenomas
and carcinoma in female mice (0.96 mg/kg/day) as point
of departure, it was concluded that the MoE is greater than
10 000 for more than 10% of the adult Belgian population,
and greater than 1500 for more than 90% of the population
[63]. While coffee consumption was a major contributor to
intake, average exposure estimates for adult consumers in
this study (380 and 494 ng/kg bw/day for the deterministic
and probabilistic approach, respectively) were lower than
those reported by Carthew et al. [62] and JECFA [65].
With regard to cholangiocarcinoma, the most sensitive
endpoint for furan carcinogenicity, it is important to note
that the average doses received from diet in humans are
only 2000-fold below furan doses causing high incidences
of cholangiocarcinoma in rats, and modeling of tumor data
resulted in an even lower MoE (Table 5) [62]. However, the
presently available tumor data for cholangiocarcinoma are in-
adequate to derive a point of departure (e.g. BMDL10) with
sufficient certainty, highlighting the need to assess formation
of cholangiocarcinoma in rodents at doses <2 mg/kg bw.
Considering the uncertainties with regard to the mode of
action of tumor formation by furan and human relevance
of furan-induced cholangiocarcinoma in the rat, and the ab-
sence of tumor data at doses lower than previously studied,
C© 2012 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.mnf-journal.com
Mol. Nutr. Food Res. 2012, 56, 1197–1211 1209
a need for risk reduction measures is indicated and furan
exposures should be reduced as requested by the ALARA
(as-low-as-reasonably-achievable) concept.
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